Search

Your search keyword '"Himmelfarb J"' showing total 484 results
Start Over Author "Himmelfarb J" Publication Year Range Last 50 years
484 results on '"Himmelfarb J"'

1. Performance Characteristics of Candidate Criteria for Hemodialysis Arteriovenous Fistula Maturation

Author

Ng, Jia Hwei, Yang, Wei, Dember, Laura M., Feldman, H., Dember, L., Farber, A., Kaufman, J., Stern, L., LeSage, P., Kivork, C., Soares, D., Malikova, M., Allon, M., Young, C., Taylor, M., Woodard, L., Mangadi, K., Roy-Chaudhury, P., Munda, R., Lee, T., Alloway, R., El-Khatib, M., Canaan, T., Pflum, A., Thieken, L., Campos-Naciff, B., Huber, T., Berceli, S., Jansen, M., McCaslin, G., Trahan, Y., Vazquez, M., Vongpatanasin, W., Davidson, I., Hwang, C., Lightfoot, T., Livingston, C., Valencia, A., Dolmatch, B., Fenves, A., Hawkins, N., Cheung, A., Kraiss, L., Kinikini, D., Treiman, G., Ihnat, D., Sarfati, M., Lavasani, I., Maloney, M., Schlotfeldt, L., Himmelfarb, J., Buchanan, C., Clark, C., Crawford, C., Hamlett, J., Kundzins, J., Manahan, L., Wise, J., Beck, G., Gassman, J., Greene, T., Imrey, P., Li, L., Alster, J., Li, M., MacKrell, J., Radeva, M., Weiss, B., Wiggins, K., Alpers, C., Hudkins, K., Wietecha, T., Robbin, M., Umphrey, H., Alexander, L., Abts, C., Belt, L., Vita, J., Hamburg, N., Duess, M., Levit, A., Higgins, H., Ke, S., Mandaci, O., Snell, C., Gravley, J., Behnken, S., Mortensen, R., Chertow, G., Besarab, A., Brayman, K., Diener-West, M., Harrison, D., Inker, L., Louis, T., McClellan, W., Rubin, J., Kusek, J., and Star, R.

Published
2023
Full Text
View/download PDF

3. Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation

Author

Feldman, H., Dember, L., Farber, A., Kaufman, J., Stern, L., LeSage, P., Kivork, C., Soares, D., Malikova, M., Allon, M., Young, C., Taylor, M., Woodard, L., Mangadi, K., Roy-Chaudhury, P., Munda, R., Lee, T., Alloway, R., El-Khatib, M., Canaan, T., Pflum, A., Thieken, L., Campos-Naciff, B., Huber, T., Berceli, S., Jansen, M., McCaslin, G., Trahan, Y., Vazquez, M., Vongpatanasin, W., Davidson, I., Hwang, C., Lightfoot, T., Livingston, C., Valencia, A., Dolmatch, B., Fenves, A., Hawkins, N., Cheung, A.K., Kraiss, L., Kinikini, D., Treiman, G., Ihnat, D., Sarfati, M., Shiu, Y.T., Terry, C., Lavasani, I., Maloney, M., Schlotfeldt, L., Himmelfarb, J., Buchanan, C., Clark, C., Crawford, C., Hamlett, J., Kundzins, J., Manahan, L., Wise, J., Beck, G., Gassman, J., Greene, T., Imrey, P., Li, L., Alster, J., Li, M., MacKrell, J., Radeva, M., Weiss, B., Wiggins, K., Alpers, C., Hudkins, K., Wietecha, T., Robbin, M., Umphrey, H., Alexander, L., Abts, C., Belt, L., Vita, J., Hamburg, N., Duess, M., Levit, A., Higgins, H., Ke, S., Mandaci, O., Snell, C., Gravley, J., Behnken, S., Mortensen, R., Chertow (Chair), G., Besarab, A., Brayman, K., Diener-West, M., Harrison, D., Inker, L., Louis, T., McClellan, W., Rubin, J., Kusek, J., Star, R., Kubiak, Rachel W., Zelnick, Leila R., Hoofnagle, Andy N., Alpers, Charles E., Terry, Christi M., Shiu, Yan-Ting, Cheung, Alfred K., de Boer, Ian H., Robinson-Cohen, Cassianne, Allon, Michael, Dember, Laura M., Feldman, Harold I., Himmelfarb, Jonathan, Huber, Thomas S., Roy-Chaudhury, Prabir, Vazquez, Miguel A., Kusek, John W., Beck, Gerald J., Imrey, Peter B., and Kestenbaum, Bryan

Published
2019
Full Text
View/download PDF

5. Dynamic Remodeling of Human Arteriovenous Fistula Wall Obtained From Magnetic Resonance Imaging During the First 6 Months After Creation

Author

Li, Yingnan, primary, He, Yong, additional, Falzon, Isabelle, additional, Fairbourn, Brayden, additional, Tingey, Spencer, additional, Imrey, Peter B., additional, Radeva, Milena K., additional, Beck, Gerald J., additional, Gassman, Jennifer J., additional, Roy-Chaudhury, Prabir, additional, Berceli, Scott A., additional, Cheung, Alfred K., additional, Shiu, Yan-Ting, additional, Feldman, H., additional, Dember, L., additional, Farber, A., additional, Kaufman, J., additional, Stern, L., additional, LeSage, P., additional, Kivork, C., additional, Soares, D., additional, Malikova, M., additional, Allon, M., additional, Young, C., additional, Taylor, M., additional, Woodard, L., additional, Mangadi, K., additional, Roy-Chaudhury, P., additional, Munda, R., additional, Lee, T., additional, Alloway, R., additional, El-Khatib, M., additional, Canaan, T., additional, Pflum, A., additional, Thieken, L., additional, Campos-Naciff, B., additional, Huber, T., additional, Berceli, S., additional, Jansen, M., additional, McCaslin, G., additional, Trahan, Y., additional, Vazquez, M., additional, Vongpatanasin, W., additional, Davidson, I., additional, Hwang, C., additional, Lightfoot, T., additional, Livingston, C., additional, Valencia, A., additional, Dolmatch, B., additional, Fenves, A., additional, Hawkins, N., additional, Cheung, A., additional, Kraiss, L., additional, Kinikini, D., additional, Treiman, G., additional, Ihnat, D., additional, Sarfati, M., additional, Lavasani, I., additional, Maloney, M., additional, Schlotfeldt, L., additional, Himmelfarb, J., additional, Buchanan, C., additional, Clark, C., additional, Crawford, C., additional, Hamlett, J., additional, Kundzins, J., additional, Manahan, L., additional, Wise, J., additional, Beck, G., additional, Gassman, J., additional, Greene, T., additional, Imrey, P., additional, Li, L., additional, Alster, J., additional, Li, M., additional, MacKrell, J., additional, Radeva, M., additional, Weiss, B., additional, Wiggins, K., additional, Alpers, C., additional, Hudkins, K., additional, Wietecha, T., additional, Robbin, M., additional, Umphrey, H., additional, Alexander, L., additional, Abts, C., additional, Belt, L., additional, Vita, J., additional, Hamburg, N., additional, Duess, M., additional, Levit, A., additional, Higgins, H., additional, Ke, S., additional, Mandaci, O., additional, Snell, C., additional, Gravley, J., additional, Behnken, S., additional, Mortensen, R., additional, Chertow, G., additional, Besarab, A., additional, Brayman, K., additional, Diener-West, M., additional, Harrison, D., additional, Inker, L., additional, Louis, T., additional, McClellan, W., additional, Rubin, J., additional, Kusek, J., additional, and Star, R., additional

Published
2022
Full Text
View/download PDF

6. Dynamic Remodeling of Human Arteriovenous Fistula Wall Obtained From Magnetic Resonance Imaging During the First 6 Months After Creation

Author

Feldman, H., Dember, L., Farber, A., Kaufman, J., Stern, L., LeSage, P., Kivork, C., Soares, D., Malikova, M., Allon, M., Young, C., Taylor, M., Woodard, L., Mangadi, K., Roy-Chaudhury, P., Munda, R., Lee, T., Alloway, R., El-Khatib, M., Canaan, T., Pflum, A., Thieken, L., Campos-Naciff, B., Huber, T., Berceli, S., Jansen, M., McCaslin, G., Trahan, Y., Vazquez, M., Vongpatanasin, W., Davidson, I., Hwang, C., Lightfoot, T., Livingston, C., Valencia, A., Dolmatch, B., Fenves, A., Hawkins, N., Cheung, A., Kraiss, L., Kinikini, D., Treiman, G., Ihnat, D., Sarfati, M., Lavasani, I., Maloney, M., Schlotfeldt, L., Himmelfarb, J., Buchanan, C., Clark, C., Crawford, C., Hamlett, J., Kundzins, J., Manahan, L., Wise, J., Beck, G., Gassman, J., Greene, T., Imrey, P., Li, L., Alster, J., Li, M., MacKrell, J., Radeva, M., Weiss, B., Wiggins, K., Alpers, C., Hudkins, K., Wietecha, T., Robbin, M., Umphrey, H., Alexander, L., Abts, C., Belt, L., Vita, J., Hamburg, N., Duess, M., Levit, A., Higgins, H., Ke, S., Mandaci, O., Snell, C., Gravley, J., Behnken, S., Mortensen, R., Chertow, G., Besarab, A., Brayman, K., Diener-West, M., Harrison, D., Inker, L., Louis, T., McClellan, W., Rubin, J., Kusek, J., Star, R., Li, Yingnan, He, Yong, Falzon, Isabelle, Fairbourn, Brayden, Tingey, Spencer, Imrey, Peter B., Radeva, Milena K., Beck, Gerald J., Gassman, Jennifer J., Roy-Chaudhury, Prabir, Berceli, Scott A., Cheung, Alfred K., and Shiu, Yan-Ting

Published
2022
Full Text
View/download PDF

7. Histopathology of Veins Obtained at Hemodialysis Arteriovenous Fistula Creation Surgery

Author

Alpers, Charles E., Imrey, Peter B., Hudkins, Kelly L., Wietecha, Tomasz A., Radeva, Milena, Allon, Michael, Cheung, Alfred K., Dember, Laura M., Roy-Chaudhury, Prabir, Shiu, Yan-Ting, Terry, Christi M., Farber, Alik, Beck, Gerald J., Feldman, Harold I., Kusek, John W., Himmelfarb, Jonathan, Dember, LM, Imrey, PB, Beck, GJ, Cheung, AK, Himmelfarb, J, Huber, TS, Kusek, JW, Roy-Chaudhury, P, Vazquez, MA, Alpers, CE, Robbin, ML, Vita, JA, Greene, T, Gassman, JJ, and Feldman, HI

Published
2017
Full Text
View/download PDF

8. Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease

Author

Lidberg, KA, Annalora, AJ, Jozic, M, Elson, DJ, Wang, L, Bammler, TK, Ramm, S, Monteiro, MB, Himmelfarb, J, Marcus, CB, Iversen, PL, Kelly, EJ, Lidberg, KA, Annalora, AJ, Jozic, M, Elson, DJ, Wang, L, Bammler, TK, Ramm, S, Monteiro, MB, Himmelfarb, J, Marcus, CB, Iversen, PL, and Kelly, EJ

Abstract

CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and hypertension, however, most investigators have considered CYP3A5*1 as active and CYP3A5*3 as an inactive allele. Observations of gender specific differences in CYP3A5*3/*3 protein expression suggest additional complexity in gene regulation that may underpin an environmentally responsive role for CYP3A5 in renal function. Reconciliation of the molecular mechanism driving conditional restoration of functional CYP3A5*3 expression from alternatively spliced transcripts, and validation of a morpholino-based approach for selectively suppressing renal CYP3A5 expression, is the focus of this work. Morpholinos targeting a cryptic splice acceptor created by the CYP3A5*3 mutation in intron 3 rescued functional CYP3A5 expression in vitro, and salt-sensitive cellular mechanisms regulating splicing and conditional expression of CYP3A5*3 transcripts are reported. The potential for a G-quadruplex (G4) in intron 3 to mediate restored splicing to exon 4 in CYP3A5*3 transcripts was also investigated. Finally, a proximal tubule microphysiological system (PT-MPS) was used to evaluate the safety profile of morpholinos in proximal tubule epithelial cells, highlighting their potential as a therapeutic platform for the treatment of renal disease.

Published
2021

9. JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells

Author

Breggia, A.C., Wojchowski, D.M., and Himmelfarb, J.

Subjects
Cellular signal transduction -- Research, Erythropoietin -- Health aspects, Ischemia -- Risk factors, Ischemia -- Prevention, Biological sciences
Abstract

Erythropoietin has emerged as a potential therapy for the treatment of ischemic tissue injury. In erythroid cells, the JAK2/Y343/STAT5 signaling axis has been shown to be necessary for stress but not steady-state erythropoiesis. The requirement for STAT5 activation in erythropoietin-mediated protection from ischemic injury has not been well-studied. To answer this question, we induced reproducible necrotic ischemic injury in primary mouse renal tubular epithelial cells (RTEC) in vitro. Using RTEC from erythropoietin receptor mutant mice with differential STAT5 signaling capabilities, we demonstrated first, that EPO administration either before or during injury significantly protects against mild-moderate but not severe necrotic cell death; and second, the JAK2/Y343/STAT5 signaling axis is required for protection against ischemic injury in primary mouse RTEC. In addition, we identified Pim-3, a prosurvival STAT5 target gene, as responsive to EPO in the noninjured kidney both in vitro and in vivo. hypoxia; ischemic preconditioning

Published
2008

14. Supplementary Material for: Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes

Author

Wang, K., Zelnick, L.R., Imrey, P.B., DeBoer, I.H., Himmelfarb, J., Allon, M.D., Cheung, A.K., Dember, L.M., Roy-Chaudhury, P., Vazquez, M.A., Kusek, J.W., Feldman, H.I., Beck, G.J., Kestenbaum, B., and Group, The Hemodialysis Fistula Maturation Study

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, cardiovascular diseases
Abstract

Background: The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. However, approximately half of AVFs fail to mature. The use of angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs) exerts favorable endothelial effects and may promote AVF maturation. We tested associations of ACE-I and ARBs, CCBs, beta-blockers, and diuretics with the maturation of newly created AVFs. Methods: We evaluated 602 participants from the Hemodialysis Fistula Maturation Study, a multi-center, prospective cohort study of AVF maturation. We ascertained the use of each medication class within 45 days of AVF creation surgery. We defined maturation outcomes by clinical use within 9 months of surgery or 4 weeks of initiating hemodialysis. Results: Unassisted AVF maturation failure without intervention occurred in 54.0% of participants, and overall AVF maturation failure (with or without intervention) occurred in 30.1%. After covariate adjustment, CCB use was associated with a 25% lower risk of overall AVF maturation failure (95% CI 3%–41% lower) but a non-significant 10% lower risk of unassisted maturation failure (95% CI 23% lower to 5% higher). ACE-I/ARB, beta-blocker, and diuretic use was not significantly associated with AVF maturation outcomes. None of the antihypertensive medication classes were associated with changes in AVF diameter or blood flow over 6 weeks following surgery. Conclusions: CCB use may be associated with a lower risk of overall AVF maturation failure. Further studies are needed to determine whether CCBs might play a causal role in improving AVF maturation outcomes.

Published
2018
Full Text
View/download PDF

15. Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation

Author

Kubiak, R.W., primary, Zelnick, L.R., additional, Hoofnagle, A.N., additional, Alpers, C.E., additional, Terry, C.M., additional, Shiu, Y.-T., additional, Cheung, A.K., additional, de Boer, I.H., additional, Robinson-Cohen, C., additional, Allon, M., additional, Dember, L.M., additional, Feldman, H.I., additional, Himmelfarb, J., additional, Huber, T.S., additional, Roy-Chaudhury, P., additional, Vazquez, M.A., additional, Kusek, J.W., additional, Beck, G.J., additional, Imrey, P.B., additional, and Kestenbaum, B., additional

Published
2019
Full Text
View/download PDF

16. Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation

Author

Kubiak, Rachel W., primary, Zelnick, Leila R., additional, Hoofnagle, Andy N., additional, Alpers, Charles E., additional, Terry, Christi M., additional, Shiu, Yan-Ting, additional, Cheung, Alfred K., additional, de Boer, Ian H., additional, Robinson-Cohen, Cassianne, additional, Allon, Michael, additional, Dember, Laura M., additional, Feldman, Harold I., additional, Himmelfarb, Jonathan, additional, Huber, Thomas S., additional, Roy-Chaudhury, Prabir, additional, Vazquez, Miguel A., additional, Kusek, John W., additional, Beck, Gerald J., additional, Imrey, Peter B., additional, Kestenbaum, Bryan, additional, Feldman, H., additional, Dember, L., additional, Farber, A., additional, Kaufman, J., additional, Stern, L., additional, LeSage, P., additional, Kivork, C., additional, Soares, D., additional, Malikova, M., additional, Allon, M., additional, Young, C., additional, Taylor, M., additional, Woodard, L., additional, Mangadi, K., additional, Roy-Chaudhury, P., additional, Munda, R., additional, Lee, T., additional, Alloway, R., additional, El-Khatib, M., additional, Canaan, T., additional, Pflum, A., additional, Thieken, L., additional, Campos-Naciff, B., additional, Huber, T., additional, Berceli, S., additional, Jansen, M., additional, McCaslin, G., additional, Trahan, Y., additional, Vazquez, M., additional, Vongpatanasin, W., additional, Davidson, I., additional, Hwang, C., additional, Lightfoot, T., additional, Livingston, C., additional, Valencia, A., additional, Dolmatch, B., additional, Fenves, A., additional, Hawkins, N., additional, Cheung, A.K., additional, Kraiss, L., additional, Kinikini, D., additional, Treiman, G., additional, Ihnat, D., additional, Sarfati, M., additional, Shiu, Y.T., additional, Terry, C., additional, Lavasani, I., additional, Maloney, M., additional, Schlotfeldt, L., additional, Himmelfarb, J., additional, Buchanan, C., additional, Clark, C., additional, Crawford, C., additional, Hamlett, J., additional, Kundzins, J., additional, Manahan, L., additional, Wise, J., additional, Beck, G., additional, Gassman, J., additional, Greene, T., additional, Imrey, P., additional, Li, L., additional, Alster, J., additional, Li, M., additional, MacKrell, J., additional, Radeva, M., additional, Weiss, B., additional, Wiggins, K., additional, Alpers, C., additional, Hudkins, K., additional, Wietecha, T., additional, Robbin, M., additional, Umphrey, H., additional, Alexander, L., additional, Abts, C., additional, Belt, L., additional, Vita, J., additional, Hamburg, N., additional, Duess, M., additional, Levit, A., additional, Higgins, H., additional, Ke, S., additional, Mandaci, O., additional, Snell, C., additional, Gravley, J., additional, Behnken, S., additional, Mortensen, R., additional, Chertow (Chair), G., additional, Besarab, A., additional, Brayman, K., additional, Diener-West, M., additional, Harrison, D., additional, Inker, L., additional, Louis, T., additional, McClellan, W., additional, Rubin, J., additional, Kusek, J., additional, and Star, R., additional

Published
2019
Full Text
View/download PDF

17. Global Cardiovascular and Renal Outcomes of Reduced GFR

Author

Thomas, B, Matsushita, K, Abate, KH, Al Aly, Z, Ärnlöv, J, Asayama, K, Atkins, R, Badawi, A, Ballew, SH, Banerjee, A, Barregård, L, Barrett Connor, E, Basu, S, Bello, AK, Bensenor, I, Bergstrom, J, Bikbov, B, Blosser, C, Brenner, H, Carrero, JJ, Chadban, S, CIRILLO, Massimo, Cortinovis, M, Courville, K, Dandona, L, Dandona, R, Estep, K, Fernandes, J, Fischer, F, Fox, C, Gansevoort, RT, Gona, PN, Gutierrez, OM, Hamidi, S, Hanson, SW, Himmelfarb, J, Jassal, SK, Jee, SH, Jha, V, Jimenez Corona, A, Jonas, JB, Kengne, AP, Khader, Y, Khang, YH, Kim, YJ, Klein, B, Klein, R, Kokubo, Y, Kolte, D, Lee, K, Levey, AS, Li, Y, Lotufo, P, El, Razek, HMA, Mendoza, W, Metoki, H, Mok, Y, Muraki, I, Muntner, PM, Noda, H, Ohkubo, T, Ortiz, A, Perico, N, Polkinghorne, K, Al Radaddi, R, Remuzzi, G, Roth, G, Rothenbacher, D, Satoh, M, Saum, KU, Sawhney, M, Schöttker, B, Shankar, A, Shlipak, M, Silva, DAS, Toyoshima, H, Ukwaja, K, Umesawa, M, Vollset, SE, Warnock, DG, Werdecker, A, Yamagishi, K, Yano, Y, Yonemoto, N, Zaki, MES, Naghavi, M, Forouzanfar, MH, Murray, CJL, Coresh, J, Vos, T, Global Burden of Disease, GFR Collaborators, CKD Prognosis Consortium, Global Burden of Disease Genitourinary Expert Group, Bello, A, Hanson, S, Vos, T., Thomas, B, Matsushita, K, Abate, Kh, Al Aly, Z, Ärnlöv, J, Asayama, K, Atkins, R, Badawi, A, Ballew, Sh, Banerjee, A, Barregård, L, Barrett Connor, E, Basu, S, Bello, Ak, Bensenor, I, Bergstrom, J, Bikbov, B, Blosser, C, Brenner, H, Carrero, Jj, Chadban, S, Cirillo, Massimo, Cortinovis, M, Courville, K, Dandona, L, Dandona, R, Estep, K, Fernandes, J, Fischer, F, Fox, C, Gansevoort, Rt, Gona, Pn, Gutierrez, Om, Hamidi, S, Hanson, Sw, Himmelfarb, J, Jassal, Sk, Jee, Sh, Jha, V, Jimenez Corona, A, Jonas, Jb, Kengne, Ap, Khader, Y, Khang, Yh, Kim, Yj, Klein, B, Klein, R, Kokubo, Y, Kolte, D, Lee, K, Levey, A, Li, Y, Lotufo, P, El, Razek, Hma, Mendoza, W, Metoki, H, Mok, Y, Muraki, I, Muntner, Pm, Noda, H, Ohkubo, T, Ortiz, A, Perico, N, Polkinghorne, K, Al Radaddi, R, Remuzzi, G, Roth, G, Rothenbacher, D, Satoh, M, Saum, Ku, Sawhney, M, Schöttker, B, Shankar, A, Shlipak, M, Silva, Da, Toyoshima, H, Ukwaja, K, Umesawa, M, Vollset, Se, Warnock, Dg, Werdecker, A, Yamagishi, K, Yano, Y, Yonemoto, N, Zaki, Me, Naghavi, M, Forouzanfar, Mh, Murray, Cjl, Coresh, J, Vos, T, Global Burden of, Disease, Gfr, Collaborator, CKD Prognosis, Consortium, Global Burden of Disease Genitourinary Expert, Group, Bello, A, Hanson, S, and Vos, T.

Subjects
Epidemiology and outcomes, cardiovascular disease, chronic dialysis, chronic kidney disease, end stage kidney disease, urologic and male genital diseases, Global Health, Kidney, Risk Assessment, female genital diseases and pregnancy complications, Cardiovascular Diseases, Risk Factors, Epidemiology and outcome, chronic dialysi, Humans, Kidney Diseases, Clinical Epidemiology, Glomerular Filtration Rate
Abstract

The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from 1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reduced GFR were calculated by pooled random effects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease, GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty interval [95% UI], 2.0 to 2.4 million). More than half of these attributable deaths were cardiovascular deaths (1.2 million; 95% UI, 1.1 to 1.4 million), whereas 0.96 million (95% UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.

Published
2016

18. Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study

Author

Allon, Michael, primary, Imrey, Peter B., additional, Cheung, Alfred K., additional, Radeva, Milena, additional, Alpers, Charles E., additional, Beck, Gerald J., additional, Dember, Laura M., additional, Farber, Alik, additional, Greene, Tom, additional, Himmelfarb, Jonathan, additional, Huber, Thomas S., additional, Kaufman, James S., additional, Kusek, John W., additional, Roy-Chaudhury, Prabir, additional, Robbin, Michelle L., additional, Vazquez, Miguel A., additional, Feldman, Harold I., additional, Feldman, H., additional, Dember, L., additional, Farber, A., additional, Kaufman, J., additional, Stern, L., additional, LeSage, P., additional, Kivork, C., additional, Soares, D., additional, Malikova, M., additional, Allon, M., additional, Young, C., additional, Taylor, M., additional, Woodard, L., additional, Mangadi, K., additional, Roy-Chaudhury, P., additional, Munda, R., additional, Lee, T., additional, Alloway, R., additional, El-Khatib, M., additional, Canaan, T., additional, Pflum, A., additional, Thieken, L., additional, Campos-Naciff, B., additional, Huber, T., additional, Berceli, S., additional, Jansen, M., additional, McCaslin, G., additional, Trahan, Y., additional, Vazquez, M., additional, Vongpatanasin, W., additional, Davidson, I., additional, Hwang, C., additional, Lightfoot, T., additional, Livingston, C., additional, Valencia, A., additional, Dolmatch, B., additional, Fenves, A., additional, Hawkins, N., additional, Cheung, A.K., additional, Kraiss, L., additional, Kinikini, D., additional, Treiman, G., additional, Ihnat, D., additional, Sarfati, M., additional, Mueller, M., additional, Lavasani, I., additional, Maloney, M., additional, Schlotfeldt, L., additional, Shiu, Y.T., additional, Terry, C., additional, Himmelfarb, J., additional, Buchanan, C., additional, Clark, C., additional, Crawford, C., additional, Hamlett, J., additional, Kundzins, J., additional, Manahan, L., additional, Wise, J., additional, Beck, G., additional, Gassman, J., additional, Greene, T., additional, Imrey, P., additional, Li, L., additional, Alster, J., additional, Li, M., additional, MacKrell, J., additional, Radeva, M., additional, Wiggins, K., additional, Weiss, B., additional, Alpers, C., additional, Hudkins, K., additional, Wietecha, T., additional, Robbin, M., additional, Umphrey, H., additional, Alexander, L., additional, Abts, C., additional, Belt, L., additional, Vita, J., additional, Hamburg, N., additional, Duess, M., additional, Levit, A., additional, Higgins, H., additional, Ke, S., additional, Mandaci, O., additional, Snell, C., additional, Gravley, J., additional, Behnken, S., additional, Mortensen, R., additional, Chertow, G., additional, Besarab, A., additional, Brayman, K., additional, Diener-West, M., additional, Harrison, D., additional, Inker, L., additional, Louis, T., additional, McClellan, W., additional, Rubin, J., additional, Kusek, J., additional, and Star, R., additional

Published
2018
Full Text
View/download PDF

19. Global cardiovascular and renal outcomes of reduced GFR.

Author

Gansevoort R.T., Al-Radaddi R., Remuzzi G., Courville K., Dandona L., Dandona R., Estep K., Fernandes J., Fischer F., Fox C., Polkinghorne K., Gona P.N., Gutierrez O.M., Hamidi S., Hanson S.W., Himmelfarb J., Jassal S.K., Jee S.H., Jha V., Jimenez-Corona A., Jonas J.B., Kengne A.P., Khader Y., Khang Y.-H., Kim Y.J., Klein B., Klein R., Kokubo Y., Kolte D., Lee K., Levey A.S., Li Y., Lotufo P., El Razek H.M.A., Mendoza W., Metoki H., Mok Y., Muraki I., Muntner P.M., Noda H., Ohkubo T., Ortiz A., Perico N., Roth G., Rothenbacher D., Satoh M., Saum K.-U., Sawhney M., Schottker B., Shankar A., Shlipak M., Silva D.A.S., Toyoshima H., Ukwaja K., Umesawa M., Vollset S.E., Warnock D.G., Werdecker A., Yamagishi K., Yano Y., Yonemoto N., Zaki M.E.S., Naghavi M., Forouzanfar M.H., Murray C.J.L., Coresh J., Vos T., Thomas B., Matsushita K., Abate K.H., Al-Aly Z., Arnlov J., Asayama K., Atkins R., Badawi A., Ballew S.H., Banerjee A., Barregard L., Barrett-Connor E., Basu S., Bello A.K., Bensenor I., Bergstrom J., Bikbov B., Blosser C., Brenner H., Carrero J.-J., Chadban S., Cirillo M., Cortinovis M., Gansevoort R.T., Al-Radaddi R., Remuzzi G., Courville K., Dandona L., Dandona R., Estep K., Fernandes J., Fischer F., Fox C., Polkinghorne K., Gona P.N., Gutierrez O.M., Hamidi S., Hanson S.W., Himmelfarb J., Jassal S.K., Jee S.H., Jha V., Jimenez-Corona A., Jonas J.B., Kengne A.P., Khader Y., Khang Y.-H., Kim Y.J., Klein B., Klein R., Kokubo Y., Kolte D., Lee K., Levey A.S., Li Y., Lotufo P., El Razek H.M.A., Mendoza W., Metoki H., Mok Y., Muraki I., Muntner P.M., Noda H., Ohkubo T., Ortiz A., Perico N., Roth G., Rothenbacher D., Satoh M., Saum K.-U., Sawhney M., Schottker B., Shankar A., Shlipak M., Silva D.A.S., Toyoshima H., Ukwaja K., Umesawa M., Vollset S.E., Warnock D.G., Werdecker A., Yamagishi K., Yano Y., Yonemoto N., Zaki M.E.S., Naghavi M., Forouzanfar M.H., Murray C.J.L., Coresh J., Vos T., Thomas B., Matsushita K., Abate K.H., Al-Aly Z., Arnlov J., Asayama K., Atkins R., Badawi A., Ballew S.H., Banerjee A., Barregard L., Barrett-Connor E., Basu S., Bello A.K., Bensenor I., Bergstrom J., Bikbov B., Blosser C., Brenner H., Carrero J.-J., Chadban S., Cirillo M., and Cortinovis M.

Abstract

The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reducedGFRwere calculated by pooled randomeffects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease,GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95%uncertainty interval [95%UI], 2.0 to 2.4million).More than half of these attributable deathswere cardiovascular deaths (1.2million; 95%UI, 1.1 to 1.4million), whereas 0.96million (95%UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.Copyright © 2017 by the American Society of Nephrology.

Published
2017

21. Epidemiology of Kidney Disease

Author

Bello, A. K., Tonelli, M., Jager, K. J., Turner, N., Goldsmith, D., Winearls, C., Lameire, N., Himmelfarb, J., Remuzzi, G., Amsterdam Cardiovascular Sciences, Amsterdam Public Health, and Medical Informatics

Published
2015

22. Multiple preoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study

Author

Farber, Alik, primary, Imrey, Peter B., additional, Huber, Thomas S., additional, Kaufman, James M., additional, Kraiss, Larry W., additional, Larive, Brett, additional, Li, Liang, additional, Feldman, Harold I., additional, Feldman, H., additional, Dember, L., additional, Farber, A., additional, Kaufman, J., additional, Stern, L., additional, LeSage, P., additional, Kivork, C., additional, Soares, D., additional, Malikova, M., additional, Allon, M., additional, Young, C., additional, Taylor, M., additional, Woodard, L., additional, Mangadi, K., additional, Roy-Chaudhury, P., additional, Munda, R., additional, Lee, T., additional, Alloway, R., additional, El-Khatib, M., additional, Canaan, T., additional, Pflum, A., additional, Thieken, L., additional, Campos-Naciff, B., additional, Huber, T., additional, Berceli, S., additional, Jansen, M., additional, McCaslin, G., additional, Trahan, Y., additional, Vazquez, M., additional, Vongpatanasin, W., additional, Davidson, I., additional, Hwang, C., additional, Lightfoot, T., additional, Livingston, C., additional, Valencia, A., additional, Dolmatch, B., additional, Fenves, A., additional, Hawkins, N., additional, Cheung, A., additional, Kraiss, L., additional, Kinikini, D., additional, Treiman, G., additional, Ihnat, D., additional, Sarfati, M., additional, Lavasani, I., additional, Maloney, M., additional, Schlotfeldt, L., additional, Himmelfarb, J., additional, Buchanan, C., additional, Clark, C., additional, Crawford, C., additional, Hamlett, J., additional, Kundzins, J., additional, Manahan, L., additional, Wise, J., additional, Beck, G., additional, Gassman, J., additional, Greene, T., additional, Imrey, P., additional, Li, L., additional, Alster, J., additional, Li, M., additional, MacKrell, J., additional, Radeva, M., additional, Weiss, B., additional, Wiggins, K., additional, Alpers, C., additional, Hudkins, K., additional, Wietecha, T., additional, Robbin, M., additional, Umphrey, H., additional, Alexander, L., additional, Abts, C., additional, Belt, L., additional, Vita, J., additional, Hamburg, N., additional, Duess, M., additional, Levit, A., additional, Higgins, H., additional, Ke, S., additional, Mandaci, O., additional, Snell, C., additional, Gravley, J., additional, Behnken, S., additional, Mortensen, R., additional, Chertow, G., additional, Besarab, A., additional, Brayman, K., additional, Diener-West, M., additional, Harrison, D., additional, Inker, L., additional, Louis, T., additional, McClellan, W., additional, Rubin, J., additional, Kusek, J., additional, and Star, R., additional

Published
2016
Full Text
View/download PDF

24. The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts

Author

Farber, Alik, primary, Tan, Tze-Woei, additional, Hu, Bo, additional, Dember, Laura M., additional, Beck, Gerald J., additional, Dixon, Bradley S., additional, Kusek, John W., additional, Feldman, Harold I., additional, Dember, L., additional, Kaufman, J., additional, Hawley, M., additional, Lauer, A., additional, LeSage, P., additional, Nathan, R., additional, Holmberg, E., additional, Braden, G., additional, Ryan, M., additional, Berkowitz, A., additional, Rahman, A., additional, Lucas, B., additional, Santos, R., additional, Reyes, B., additional, Greenberg, A., additional, Berkoben, M., additional, Kovalik, E., additional, Lawson, J., additional, Middleton, J., additional, Schwab, S., additional, Schumm, D., additional, Adams, S., additional, Gitter, K., additional, Cantaffa, T., additional, Quarles, A., additional, Work, J., additional, Rhodes, S., additional, Himmelfarb, J., additional, Whiting, J., additional, Kane, J., additional, Freedman, S., additional, Violette, R., additional, Cyr-Alves, H., additional, Garrison, K., additional, Martin, K., additional, Schmitz, P., additional, Jenkins, V., additional, Cotton, J., additional, Husband, E., additional, Allon, M., additional, Robbin, M., additional, Lockhart, M., additional, Casey, B., additional, Newsome, J., additional, Dixon, B., additional, Franzwa, B., additional, Hunsicker, L., additional, Hoballah, J., additional, Katz, D., additional, Sharp, W., additional, Kresowik, T., additional, Wu, Y., additional, Rayhill, S., additional, Pflederer, T., additional, DuPage, K., additional, Welch, K., additional, Darras, F., additional, Banqero, A., additional, Ketel, B., additional, Wounded Arrow, A., additional, Vazquez, M., additional, Davidson, I., additional, Toto, R., additional, Littmon, L., additional, Ying, C., additional, Lightfoot, T., additional, Quinones, H., additional, Saxena, R., additional, Clagett, P., additional, Valentine, J., additional, Dolmatch, B., additional, Thompson, J., additional, Fenves, A., additional, Pearl, G., additional, Ikizler, A., additional, Egbert, P., additional, McNeil, J., additional, Holmes, D., additional, Freiberger, W., additional, Delmez, J., additional, Windus, D., additional, Coyne, D., additional, Rothstein, M., additional, Shenoy, S., additional, Creaghan, R., additional, Lluka, B., additional, Kusek, J., additional, Meyers, C., additional, Feldman, H., additional, Beck, G., additional, Gassman, J., additional, Greene, T., additional, Hu, B., additional, Bi, S., additional, Liu, A., additional, Radeva, M., additional, Tuason, L., additional, Weiss, B., additional, Levin, N., additional, Besarab, A., additional, Chertow, G., additional, Diener-West, M., additional, Louis, T., additional, McClellan, W., additional, and Stehman-Breen, C., additional

Published
2015
Full Text
View/download PDF

27. Acute kidney injury / Nephrocalcinosis

Author

Claure-Del Granado, R., primary, Macedo, E., additional, Soroko, S., additional, Kim, Y. W., additional, Chertow, G. M., additional, Himmelfarb, J., additional, Ikizler, T. A., additional, Paganini, E. P., additional, Mehta, R. L., additional, Martin-Moreno, P. L., additional, Garcia-Fernandez, N., additional, Varo, N., additional, Nunez-Cordoba, J. M., additional, Haase-Fielitz, A., additional, Mertens, P. R., additional, Plass, M., additional, Kuppe, H., additional, Hetzer, R., additional, Westerman, M., additional, Prowle, J. R., additional, Bellomo, R., additional, Haase, M., additional, Bolignano, D., additional, Zanoli, L., additional, Rastelli, S., additional, Marcantoni, C., additional, Coppolino, G., additional, Lucisano, G., additional, Tamburino, C., additional, Battaglia, E., additional, and Castellino, P., additional

Published
2011
Full Text
View/download PDF

33. A new allocation plan for renal transplantation

Author

Delmonico, F.L, primary, Harmon, W.E, additional, Lorber, M.I, additional, Goguen, J, additional, Mah, H, additional, Himmelfarb, J, additional, Lipkowitz, G, additional, Valliere, S, additional, Bow, L, additional, Milford, E.L, additional, and Rohrer, R.J, additional

Published
1999
Full Text
View/download PDF

41. Hemodialysis access failure: a call to action--revisited.

Author

Hakim RM and Himmelfarb J

Abstract

Eighty-two percent (82%) of patients initiating hemodialysis in the United States in 2006 did so with a catheter as the functioning access. Even in patients who have been followed by nephrologists for 6 months or more, 74% of patients initiated dialysis with a catheter. This is a multifactoral problem that requires attention and solutions from all stakeholders, including the nephrologist, the vascular surgeon, the hospital, and the insurance industry, as well as the patient and family. We propose a series of specific proposals that include a process for the timely referral and timely placement of a permanent access based on the patient's estimated or measured glomerular filtration rate (GFR), and a 'pay-for-performance' measure for vascular surgeons and nephrologists who admit patients with functional permanent accesses; such pay for performance would place a higher value for patients who are admitted with a functional arteriovenous (AV) fistula than for patients who are admitted with an AV graft. We also propose that hospitals develop a less permissive process for placement of PICC (peripherally inserted central catheters) lines in patients with GFR <60 ml/min and to consider surgery for access placement as 'urgent'. Finally, a more proactive educational process for patients and their families, including an 'informed non-consent' for patients who defer placement of a permanent access needs to be considered. The morbidity, mortality, and health-care costs associated with prolonged catheter use mandate urgent attention to this problem. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

43. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.

Author

Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI, and Dialysis Access Consortium Study Group

Abstract

Context: The arteriovenous fistula is the preferred type of vascular access for hemodialysis because of lower thrombosis and infection rates and lower health care expenditures compared with synthetic grafts or central venous catheters. Early failure of fistulas due to thrombosis or inadequate maturation is a barrier to increasing the prevalence of fistulas among patients treated with hemodialysis. Small, inconclusive trials have suggested that antiplatelet agents may reduce thrombosis of new fistulas.Objective: To determine whether clopidogrel reduces early failure of hemodialysis fistulas.Design, Setting, and Participants: Randomized, double-blind, placebo-controlled trial conducted at 9 US centers composed of academic and community nephrology practices in 2003-2007. Eight hundred seventy-seven participants with end-stage renal disease or advanced chronic kidney disease were followed up until 150 to 180 days after fistula creation or 30 days after initiation of dialysis, whichever occurred later.Intervention: Participants were randomly assigned to receive clopidogrel (300-mg loading dose followed by daily dose of 75 mg; n = 441) or placebo (n = 436) for 6 weeks starting within 1 day after fistula creation.Main Outcome Measures: The primary outcome was fistula thrombosis, determined by physical examination at 6 weeks. The secondary outcome was failure of the fistula to become suitable for dialysis. Suitability was defined as use of the fistula at a dialysis machine blood pump rate of 300 mL/min or more during 8 of 12 dialysis sessions.Results: Enrollment was stopped after 877 participants were randomized based on a stopping rule for intervention efficacy. Fistula thrombosis occurred in 53 (12.2%) participants assigned to clopidogrel compared with 84 (19.5%) participants assigned to placebo (relative risk, 0.63; 95% confidence interval, 0.46-0.97; P = .018). Failure to attain suitability for dialysis did not differ between the clopidogrel and placebo groups (61.8% vs 59.5%, respectively; relative risk, 1.05; 95% confidence interval, 0.94-1.17; P = .40).Conclusion: Clopidogrel reduces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proportion of fistulas that become suitable for dialysis. Trial Registration clinicaltrials.gov Identifier: NCT00067119. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

44. Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients.

Author

Inrig JK, Patel UD, Gillespie BS, Hasselblad V, Himmelfarb J, Reddan D, Lindsay RM, Winchester JF, Stivelman J, Toto R, Szczech LA, Inrig, Jula K, Patel, Uptal D, Gillespie, Barbara S, Hasselblad, Vic, Himmelfarb, Jonathan, Reddan, Donal, Lindsay, Robert M, Winchester, James F, and Stivelman, John

Abstract

Background: Hypertension is common in hemodialysis patients; however, the relationship between interdialytic weight gain (IDWG) and blood pressure (BP) is incompletely characterized. This study seeks to define the relationship between IDWG and BP in prevalent hemodialysis subjects.Study Design, Setting,& Participants: This study used data from 32,295 dialysis sessions in 442 subjects followed up for 6 months in the Crit-Line Intradialytic Monitoring Benefit (CLIMB) Study.Outcomes& Measurements: Mixed linear regression was used to analyze the relationship between percentage of IDWG (IDWG [%] = [current predialysis weight - previous postdialysis weight]/dry weight * 100) as the independent variable and systolic BP (SBP) and predialysis - postdialysis SBP (deltaSBP) as dependent variables.Results: In unadjusted analyses, every 1% increase in percentage of IDWG was associated with a 1.00 mm Hg (95% confidence interval [CI], +/-0.24) increase in predialysis SBP (P < 0.0001), 0.65 mm Hg (95% CI, +/-0.24) decrease in postdialysis SBP (P < 0.0001), and 1.66 mm Hg (95% CI, +/-0.25) increase in deltaSBP (P < 0.0001). After controlling for other significant predictors of SBP, every 1% increase in percentage of IDWG was associated with a 1.00 mm Hg (95% CI, +/-0.24) increase in predialysis SBP (P < 0.0001) and a 1.08 mm Hg (95% CI, +/-0.22) increase in deltaSBP with hemodialysis (P < 0.0001). However, in subjects with diabetes as the cause of end-stage renal disease, subjects with lower creatinine levels, and older subjects, the magnitude of the association between percentage of IDWG and predialysis SBP was less pronounced. The magnitude of percentage of IDWG on deltaSBP was less pronounced in younger subjects and subjects with lower dry weights. Results were similar with diastolic BP.Limitations: Hemodialysis BP measurements are imprecise estimates of BP and true hemodynamic burden in dialysis subjects.Conclusions: In prevalent hemodialysis subjects, increasing percentage of IDWG is associated with increases in predialysis BP and BP changes with hemodialysis; however, the magnitude of the relationship is modest and modified by other clinical factors. Thus, although overall volume status may impact on BP to a greater extent, day-to-day variations in weight gain have a modest role in BP increases in prevalent subjects with end-stage renal disease. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

49. Baseline Oxysterols and Other Markers of Oxidative Stress, Inflammation and Malnutrition in the Vitamin E and Intima Media Thickness Progression in End-Stage Renal Disease (VIPER) Cohort

Author

Boaz, M., Iuliano, L., Himmelfarb, J., Matas, Z., Micheletta, F., McMonagle, E., Friedman, V., Natoli, S., Gvirtz, G., Biro, A., Smetana, S., Sabo, G., Gafter, U., and Weinstein, T.

Abstract

AbstractBackground and Objectives: Oxysterols are markers of oxidative stress, levels of which have not yet been reported in hemodialysis (HD) patients. This study was designed to compare levels of the oxysterols 7-ketocholesterol (7KC) and 7β-hydroxycholesterol (7βOH) between a cohort of HD patients and healthy controls. Methods: This nested cross-sectional study reflects baseline (pre-intervention) values for markers of oxidative stress, inflammation and nutrition status in the 160-member vitamin E and carotid intima media thickness progression in end-stage renal disease (VIPER) cohort (age 64.1 ± 8.8, 33.5% female). Age- and sex-matched healthy volunteers served as controls. Plasma oxysterols 7KC and 7βOH were determined by isotope dilution gas chromatography/mass spectrometry. Results: Despite higher plasma α-tocopherol levels in HD patients than controls (36.0 ± 9.3 vs. 31.8 ± 8.4 μmol/l, p = 0.007), 7KC levels (9.8 ± 6.9 vs. 5.9 ± 2.8 nmol/mmol cholesterol, p &lt; 0.0001) and 7βOH levels (8.7 ± 4.3 vs. 2.7 ± 1.6 nmol/mmol cholesterol, p &lt; 0.0001) were higher in HD patients. The oxysterol 7βOH was significantly, inversely associated with prealbumin (r = –0.18, p = 0.03), though neither oxysterol was significantly associated with any other marker of oxidative stress, inflammation or nutrition status and did not discriminate for CVD in HD patients. Conclusions: Elevated levels of the oxysterols 7KC and 7βOH indicate that HD patients are in a state of oxidative stress compared to healthy controls. However, oxysterols 7KC and 7βOH did not appear to contribute additional information about oxidative stress among HD patients.Copyright © 2005 S. Karger AG, Basel

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results